Hormonal
Tirzepatide produces significantly greater weight loss than semaglutide and liraglutide in patients with obesity or type 2 diabetes.
If you are struggling with obesity or type 2 diabetes, tirzepatide (administered weekly at doses up to 15 mg) has demonstrated superior weight loss capabilities compared to semaglutide and liraglutide in clinical trials. To maximize results, combine this pharmacotherapy with lifestyle changes, including a caloric deficit, regular physical activity, and behavioral modifications.
The research proved that tirzepatide is more effective in reducing body weight compared to semaglutide and liraglutide
Why this rating
Based on a literature review citing high-impact RCTs (STEP 1, SCALE, SURPASS-2), though it is a review rather than a primary trial.
Source
Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
Karolina Baran et al. · Quality in Sport · 2024
DOI 10.12775/qs.2024.30.56469
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →